[{"orgOrder":0,"company":"Tyligand Bioscience","sponsor":"Context Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Agreement","leadProduct":"Onapristone","moa":"Progesterone receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Tyligand Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tyligand Bioscience \/ Context Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Tyligand Bioscience \/ Context Therapeutics"},{"orgOrder":0,"company":"Tyligand Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"TSN084","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Tyligand Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Tyligand Bioscience \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Tyligand Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"Tyligand Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"TSN084","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Tyligand Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Tyligand Bioscience \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Tyligand Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"Tyligand Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"TSN1611","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tyligand Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tyligand Bioscience \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Tyligand Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"Tyligand Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"TSN1611","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tyligand Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tyligand Bioscience \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Tyligand Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"Tyligand Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"TSN222","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tyligand Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Tyligand Bioscience \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Tyligand Bioscience \/ Undisclosed"}]